DOCSLIB.ORG

BI1071, a Novel Nur77 Modulator, Induces Apoptosis of Cancer Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BI1071, a Novel Nur77 Modulator, Induces Apoptosis of Cancer Cells Published OnlineFirst March 29, 2019; DOI: 10.1158/1535-7163.MCT-18-0918 Small Molecule Therapeutics Molecular Cancer Therapeutics BI1071, a Novel Nur77 Modulator, Induces Apoptosis of Cancer Cells by Activating the Nur77-Bcl-2 Apoptotic Pathway Xiaohui Chen1, Xihua Cao2, Xuhuang Tu1, Gulimiran Alitongbieke1, Zebin Xia2, Xiaotong Li1, Ziwen Chen1,MeimeiYin,DanXu1, Shangjie Guo1, Zongxi Li1, Liqun Chen1,XindaoZhang1,DingyuXu1, Meichun Gao1,JieLiu1, Zhiping Zeng1, Hu Zhou1,YingSu2, and Xiao-kun Zhang1,2 Abstract Nur77 (also called TR3 or NGFI-B), an orphan member of indole-3-carbinol metabolite, as a modulator of the Nur77- the nuclear receptor superfamily, induces apoptosis by trans- Bcl-2 apoptotic pathway. BI1071 binds Nur77 with high locating to mitochondria where it interacts with Bcl-2 to affinity, promotes Nur77 mitochondrial targeting and inter- convert Bcl-2 from an antiapoptotic to a pro-apoptotic mol- action with Bcl-2, and effectively induces apoptosis of cancer ecule. Nur77 posttranslational modification such as phos- cells in a Nur77- and Bcl-2–dependent manner. Studies with phorylation has been shown to induce Nur77 translocation animal model showed that BI1071 potently inhibited the from the nucleus to mitochondria. However, small molecules growth of tumor cells in animals through its induction of that can bind directly to Nur77 to trigger its mitochondrial apoptosis. Our results identify BI1071 as a novel Nur77- localization and Bcl-2 interaction remain to be explored. Here, binding modulator of the Nur77-Bcl-2 apoptotic pathway, we report our identification and characterization of DIM-C- which may serve as a promising lead for treating cancers with þ À pPhCF3 MeSO3 (BI1071), an oxidized product derived from overexpression of Bcl-2. Introduction Bcl-2 in regulating the apoptosis of cancer cells and in the resistance of cancer cells to a variety of radio- and chemother- Nur77 (NR4A1;alsoknownasNGFI-BandTR3)isperhaps apeutic agents, understanding how the Nur77-Bcl-2 apoptotic the most potent apoptotic member of the nuclear receptor pathway is regulated and discovering its small-molecule mod- superfamily (1–8). The death effect of Nur77 was initially ulators may offer new strategies to develop effective cancer recognized during studying the apoptosis of immature thymo- therapeutics. However, small molecules that can activate the cytes, T-cell hybridomas (9, 10). Later, we found that Nur77 Nur77-Bcl-2 apoptotic pathway by binding to Nur77 to trigger mediates the death effect of the retinoid-related molecule Nur77 mitochondrial translocation and interaction with Bcl-2 AHPN (also called CD437) in cancer cells (11). Furthermore, have not been reported. we discovered a nongenomic action of Nur77, in which Nur77 As an orphan nuclear receptor, Nur77 lacks a canonical migrates from the nucleus to the cytoplasm, where it targets ligand-binding pocket (LBP; refs. 16, 17), which excludes small mitochondria to trigger cytochrome c release and apoptosis in molecules from binding to Nur77 to regulate Nur77 functions cancer cells (12–14). Further studies demonstrated in various via the canonical LBP-binding mechanism. Recent advance has cancer types that such a Nur77 mitochondrial apoptotic path- revealed the existence of alternate small-molecule binding way is characterized by its interaction with Bcl-2 and the regions on the surface of nuclear receptors, and compounds conversion of Bcl-2 from an antiapoptotic molecule to a that bind to alternate sites other than LBP have been identified pro-apoptotic molecule (6, 15). Given the pivotal role of for some nuclear receptors (18, 19), including Nur77 (20–24). These developments inspire us to discover Nur77-binding compounds that can regulate the Nur77-Bcl-2 apoptotic path- 1 School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Inno- way.Here,wereportthatasaltformofa3,30-diindolymethane vative Drug Target Research, Xiamen University, Xiamen, China. 2Cancer Center, (DIM) derivative (di(1H-indol-3-yl)(4-(trifluoromethyl)phe- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California. nyl)methane; named BI1071 here) can bind to Nur77 to induce Note: Supplementary data for this article are available at Molecular Cancer apoptosis of cancer cells through the Nur77-Bcl-2 apoptotic Therapeutics Online (http://mct.aacrjournals.org/). pathway. BI1071 binds to Nur77 at submicromolar concentra- X. Chen and X. Cao contributed equally to this article. tion and induces apoptosis that is dependent on the expression Corresponding Authors: Ying Su, Sanford Burnham Prebys Medical Discovery of both Nur77 and Bcl-2. BI1071 also effectively inhibits the Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037; E-maill: growth of tumor cells in animals. Moreover, BI1071 binding to [email protected] and Xiao-kun Zhang, Xiamen University, Xiamen, China; Nur77 induces not only its mitochondrial targeting but also its E-mail: [email protected] interaction with Bcl-2. Our results therefore identify BI1071 as doi: 10.1158/1535-7163.MCT-18-0918 the first Nur77-binding small molecule that promotes the Ó2019 American Association for Cancer Research. Nur77-Bcl-2 apoptotic pathway. 886 Mol Cancer Ther; 18(5) May 2019 Downloaded from mct.aacrjournals.org on September 26, 2021. © 2019 American Association for Cancer Research. Published OnlineFirst March 29, 2019; DOI: 10.1158/1535-7163.MCT-18-0918 A New Activator of the Nur77-Bcl-2 Apoptotic Pathway Materials and Methods Generation of Nur77 and Bcl-2 knockout cells by CRISPR/Cas9 system Cell culture Knocking out Nur77 and Bcl-2 from HeLa cells used the The following cell lines are used in our study. HCT116 colon CRISPR/Cas9 system. gRNA targeting sequence of Nur77 (50- cancer, MDA-MB-231, HS578T, BT549, MCF-7, and T47D breast ACCTTCATGGACGGCTACAC-30) and Bcl-2 (50-GAGAACAGGG- cancer, breast epithelial cell line MCF-10A, HeLa ovarian cancer, TACGATAACC-30) was cloned into gRNA cloning vector Px330 mouse embryonic fibroblast (MEF) cells and HEK293T embryonic (Addgene, 71707) and confirmed by sequencing. The accession cells were cultured in DMEM, whereas ZR-75-1, HCC1937 breast numbers of Nur77 and Bcl-2 are NM 001202233 and cancer and SW480 colon cancer were cultured in RPIM-1640 - NM 000633.2 respectively. To screen for cells lacking Nur77 or medium containing 10% FBS. Human colonic epithelial cells - Bcl-2, HeLa cells were transfected with control vector and gRNA (HCoEpiC) were cultured in colonic epithelial cell medium (CoE- expression vectors, followed by G418 selection (0.5 mg/mL). piCM, Cat. #2951). Cell lines HCT116 (ATCC, CCL-247), SW480 Single colonies were subjected to Western blotting using anti- (ATCC, CCL-228), and HEK293T (ATCC, CRL-11268) were Nur77 and anti–Bcl-2 antibody to select knockout cells. obtained from the ATCC. Cell lines MCF-10A (SCSP-660), MDA-MB-231 (SCSP-5043), HeLa (TCHu187), HS578T Cell viability determination and cell death assay (TCHu127), BT549 (TCHu 93), MCF-7 (SCSP-531), ZR-75-1 Cell viability was analyzed by using colorimetric 3-(4,5- (TCHu126), T47D (TCHu 87), and HCC1937 (TCHu148) were dimethylthiazol-dimethylthiazol-2-yl)-2,5-diphenyletetrazolium obtained from Chinese Academy of Science Shanghai Cell Bank on Bromide (MTT) assay as described previously (12–14, 24). December 09, 2016. Cell line HCoEpiC was obtained from Scien- ceCell (Cat. #2950) on October 05, 2018. MEF cells were isolated Mammalian one hybrid assay from embryonic day 13 wild-type (WT) and Nur77 knock out (KO) HEK293T cells were co-transfected with pG5 Luciferase reporter mice. The cells were grown in the cell incubator with 5% CO2 at together with the plasmid encoding RXRa-LBD fused with the 37 C. Sub-confluent cells with exponential growth were used Gal4 DNA-binding domain and other expression plasmids as throughout the experiments. Cells plated onto cell culture dishes described previously (18, 25). After transfection, cells were treated and kept in 10% FBS for 24 hours were treated with compounds or with DMSO or BI1071, and assayed by using the Dual-Luciferase transfected with plasmids. Cell transfection was carried out by Reporter Assay System (Promega). Transfection efficiency was using Lipofectamin 2000 according to the manufacturer's instruc- normalized to Renilla luciferase activity. tion. The cells were tested by using Mycoplasma Hoechst Stain Assay kit (Beyotime, C0296) every 6 months. We added the Hoechest Cell fractionation solution to stain the cells with 50% density at room temperature for For cellular fractionation (12–14, 24), cells were lysed in cold 30 minutes and then used the confocal microscope to observe the buffer A (10 mmol/L HEPES-KOH (pH 7.9), 1.5 mmol/L MgCl , cells. In the cells without Mycoplasma infection, only the blue 2 10 mmol/L KCl, 0.5 mmol/L dithiothreitol) with a cocktail of fluorescence of the nucleus was observed. Filamentous blue fluo- proteinase inhibitors on ice for 10 minutes as described previ- rescence can be observed around the nucleus in Mycoplasma con- ously. Cytoplasmic fraction was collected by centrifuging at 6,000 taminated cell samples. The cells were prevented from Mycoplasma rpm for 10 minutes. Pellets containing nuclei were resuspended in infection by using plasmocin (Invivogen, ant-mpt). No positive cold high-salt buffer C (20 mmol/L HEPES-KOH (pH 7.9), 25% Mycoplasma tests was observed during the time of our experiments. glycerol, 420 mmol/L NaCl, 1.5 mmol/L MgCl2, 0.2 mmol/L EDTA, 0.5 mmol/L dithiothreitol) with a cocktail of proteinase Plasmids inhibitors on ice for 30 minutes. Plasmids pcmv-myc-Nur77, GFP-Nur77, GFP-Nur77/LBD, GST-Bcl-2, pcmv-myc-Bcl-2, Flag-cmv-Bcl-2 were constructed as GST-pull down – described (12 14, 24). Plasmids pcmv-myc-Nur77/H372D, GST or GST-Bcl-2 fusion protein (0.5 mg) was immobilized on pcmv-myc-Nur77/H372A, pcmv-myc-Nur77/Y453L, pcmv-myc- glutathione-Sepharose beads and incubated with purified His- Nur77/C566K were constructed by using the PCR and Quick- Nur77-LBD (0.2 mg) in the presence of different concentration of Chang mutagenesis kit.
Load more

Recommended publications
  • The Rise and Fall of the Bovine Corpus Luteum
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Spring 5-6-2017 The Rise and Fall of the Bovine Corpus Luteum Heather Talbott University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Biochemistry Commons, Molecular Biology Commons, and the Obstetrics and Gynecology Commons Recommended Citation Talbott, Heather, "The Rise and Fall of the Bovine Corpus Luteum" (2017). Theses & Dissertations. 207. https://digitalcommons.unmc.edu/etd/207 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE RISE AND FALL OF THE BOVINE CORPUS LUTEUM by Heather Talbott A DISSERTATION Presented to the Faculty of the University of Nebraska Graduate College in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Biochemistry and Molecular Biology Graduate Program Under the Supervision of Professor John S. Davis University of Nebraska Medical Center Omaha, Nebraska May, 2017 Supervisory Committee: Carol A. Casey, Ph.D. Andrea S. Cupp, Ph.D. Parmender P. Mehta, Ph.D. Justin L. Mott, Ph.D. i ACKNOWLEDGEMENTS This dissertation was supported by the Agriculture and Food Research Initiative from the USDA National Institute of Food and Agriculture (NIFA) Pre-doctoral award; University of Nebraska Medical Center Graduate Student Assistantship; University of Nebraska Medical Center Exceptional Incoming Graduate Student Award; the VA Nebraska-Western Iowa Health Care System Department of Veterans Affairs; and The Olson Center for Women’s Health, Department of Obstetrics and Gynecology, Nebraska Medical Center.
    [Show full text]
  • Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.22.109017; this version posted May 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Assessment of NR4A Ligands that Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1 Paola Munoz-Tello 1, Hua Lin 2,3, Pasha Khan 2, Ian Mitchelle S. de Vera 1,4, Theodore M. Kamenecka 2, and Douglas J. Kojetin 1,2,* 1 Department of Integrative Structural and Computational Biology, The Scripps Research Institute, Jupiter, FL, 33458, USA 2 Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, USA 3 Current address: Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University, Fuzhou 350117, China 4 Current address: Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA * Correspondence: [email protected] as ligands that increase Nurr1 transcription in human neuroblastoma SK- ABSTRACT N-BE(2)-C cells (11). Amodiaquine improves behavioral alterations in a Nurr1/NR4A2 is an orphan nuclear receptor transcription factor im- Parkinson’s disease animal model (11) and improves neuropathology and plicated as a potential drug target for neurological disorders including memory impairment in an Alzheimer’s disease animal model (12). Alzheimer’s and Parkinson’s diseases. Previous studies identified small molecule modulators of NR4A nuclear receptors including Nurr1 and Amodiaquine is the most potent and efficacious Nurr1 agonist of the Nur77/NR4A1; it remains unclear whether these ligands affect Nurr1 4-amino-7-chloroquinoline compounds, but these compounds are not through direct binding or indirect non-binding mechanisms.
    [Show full text]
  • Chromosomal Instability in Acute Myeloid Leukemia
    cancers Review Chromosomal Instability in Acute Myeloid Leukemia Mateus de Oliveira Lisboa 1 , Paulo Roberto Slud Brofman 1, Ana Teresa Schmid-Braz 2, Aline Rangel-Pozzo 3,* and Sabine Mai 3,* 1 Core for Cell Technology, School of Medicine, Pontifícia Universidade Católica do Paraná—PUCPR, Curitiba 80215-901, Paraná, Brazil; [email protected] (M.d.O.L.); [email protected] (P.R.S.B.) 2 Hospital das Clínicas, Universidade Federal do Paraná, Curitiba 80060-240, Paraná, Brazil; [email protected] 3 Department of Physiology and Pathophysiology, University of Manitoba, Cell Biology, CancerCare Manitoba Research Institute, Winnipeg, MB R3C 2B7, Canada * Correspondence: [email protected] (A.R.-P.); [email protected] (S.M.); Tel.: +1-(204)787-4125 (S.M.) Simple Summary: Chromosome instability (CIN) is an increased rate where chromosome acquire alterations due to errors in cell division. CIN creates genetic and cytogenetic diversity and is a common feature in hematological malignancies such as acute myeloid leukemia (AML). Low to moderate levels of CIN seems to be well tolerated and can promote cancer proliferation, genetic diversity, and tumor evolution. However, high levels of CIN seems to be lethal, where enhancing CIN could improve AML treatment. However, little is known about CIN in AML. Our review focus on CIN studies in AML, their prognostic results, as well as the use of CIN as a therapeutic target in AML. Abstract: Chromosomal instability (CIN), the increasing rate in which cells acquire new chromoso- mal alterations, is one of the hallmarks of cancer. Many studies highlighted CIN as an important Citation: de Oliveira Lisboa, M.; mechanism in the origin, progression, and relapse of acute myeloid leukemia (AML).
    [Show full text]
  • By Submitted in Partial Satisfaction of the Requirements for Degree of in In
    BCL6 maintains thermogenic capacity of brown adipose tissue during dormancy by Vassily Kutyavin DISSERTATION Submitted in partial satisfaction of the requirements for degree of DOCTOR OF PHILOSOPHY in Biomedical Sciences in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Approved: ______________________________________________________________________________Eric Verdin Chair ______________________________________________________________________________Ajay Chawla ______________________________________________________________________________Ethan Weiss ______________________________________________________________________________ ______________________________________________________________________________ Committee Members Copyright 2019 by Vassily Kutyavin ii Dedicated to everyone who has supported me during my scientific education iii Acknowledgements I'm very grateful to my thesis adviser, Ajay Chawla, for his mentorship and support during my dissertation work over the past five years. Throughout my time in his lab, I was always able to rely on his guidance, and his enthusiasm for science was a great source of motivation. Even when he was traveling, he could easily be reached for advice by phone or e- mail. I am particularly grateful for his help with writing the manuscript, which was probably the most challenging aspect of graduate school for me. I am also very grateful to him for helping me find a postdoctoral fellowship position. Ajay's inquisitive and fearless approach to science have been a great inspiration to me. In contrast to the majority of scientists who focus narrowly on a specific topic, Ajay pursued fundamental questions across a broad range of topics and was able to make tremendous contributions. My experience in his lab instilled in me a deep appreciation for thinking about the entire organism from an evolutionary perspective and focusing on the key questions that escape the attention of the larger scientific community. As I move forward in my scientific career, there is no doubt that I will rely on him as a role model.
    [Show full text]
  • Inhibition of Nr4a Receptors Enhances Anti-Tumor Immunity by Breaking Treg-Mediated Immune Tolerance
    Author Manuscript Published OnlineFirst on March 20, 2018; DOI: 10.1158/0008-5472.CAN-17-3102 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Inhibition of Nr4a receptors enhances anti-tumor immunity by breaking Treg-mediated immune tolerance Sana Hibino1, Shunsuke Chikuma1, Taisuke Kondo1, Minako Ito1, Hiroko Nakatsukasa1, Setsuko Omata-Mise1, and Akihiko Yoshimura1,2 1Department of Microbiology and Immunology, Keio University School of Medicine 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan 2Correspondence to: Akihiko Yoshimura, PhD Department of Microbiology and Immunology Keio University School of Medicine 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan Phone: +81-3-5363-3483 Fax: +81-3-5360-1508 Email: [email protected] Running title: Promotion of anti-tumor immunity by Nr4a inhibition Keywords: regulatory T cell, immune tolerance, tumor immunology, transcription factors, animal models of cancer Conflict of Interest Statement: The authors declare no potential conflicts of interest. Acknowledgements: We thank N. Shiino, M. Ohkura, Y. Tokifuji, and Y. Hirata for their technical assistance. This work was supported by JSPS KAKENHI (S) 17H06175 (to A. Yoshimura), Advanced Research & Development Programs for Medical Innovation (AMED-CREST) JP17gm0510019 (to A. Yoshimura), the Takeda Science Foundation (to A. Yoshimura), the Uehara Memorial Foundation (to A. Yoshimura), the SENSHIN Medical Research Foundation (to A. Yoshimura), and Grant-in-Aid for Scientific Research on Innovative Areas 17H05801 (to S. Chikuma). 1 Downloaded from cancerres.aacrjournals.org on October 7, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on March 20, 2018; DOI: 10.1158/0008-5472.CAN-17-3102 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Supplemental Text and Figures
    Supplemental Materials and Methods Experimental bone metastasis assay Primary PCa cells were sorted by GFP marker from mTmG+ tumors, and 105 cells in 20μL PBS were injected using Hamilton syringe into the tibia of 6-week old NSG mice. Mice were monitored biweekly for moribund signs for euthanasia and organ harvest. Noninvasive mouse and ex vivo imaging MRI imaging with Bruker ICON and fluorescence imaging of fresh organs with metastasis enumeration were recently described (Lu et al. 2017). Primary prostate cell sphere formation assay Isolate of primary cells from prostate, culture and counting of prostatospheres on Matrigel were performed as described (Lukacs et al. 2010). For organoid culture assay, we followed a published matrigel embedding method (Chua et al. 2014). RNA-Seq and differential gene expression Total RNA was isolated from prostate tumors using Direct-zol RNA MiniPrep Kit (Zymo Research) and processed for stranded total RNA-Seq using Illumina HiSeq 4000 at Sequencing and Microarray Facility at MD Anderson Cancer Center. The differential expression analysis was performed using the DESeq2 package of R. P-values obtained after multiple binomial tests were adjusted using BH method. Significant genes are defined by using a cut-off of 0.05 on the BH corrected p-value and an absolute log2 fold change value of at least 1.5. Histology and western blot H&E stain, immunohistochemical (IHC) and western blot were performed as previously described (Ding et al. 2011; Wang et al. 2016). Primary antibodies for IHC include Ki67 (Fisher, RM-9106-S1), cleaved caspase 3 (Cell Signaling Technology aka CST, 9661), cyclin D1 (Fisher, clone SP4), TGFBR2 (Abcam, ab61213), BMPR2 (Abcam, ab130206), AR (EMD Millipore, 06-680), phospho- Akt (CST, 4060), GFP (CST, 2956), E-Cadherin (CST, 14472).
    [Show full text]
  • The CBP KIX Domain Regulates Long-Term Memory and Circadian Activity Snehajyoti Chatterjee1,2,3†, Christopher C
    Chatterjee et al. BMC Biology (2020) 18:155 https://doi.org/10.1186/s12915-020-00886-1 RESEARCH ARTICLE Open Access The CBP KIX domain regulates long-term memory and circadian activity Snehajyoti Chatterjee1,2,3†, Christopher C. Angelakos4,5†, Ethan Bahl6,7, Joshua D. Hawk4,5, Marie E. Gaine3, Shane G. Poplawski4,5,8, Anne Schneider-Anthony1,2, Manish Yadav3, Giulia S. Porcari5, Jean-Christophe Cassel1, K. Peter Giese9, Jacob J. Michaelson6,10,11,12, Lisa C. Lyons3,13, Anne-Laurence Boutillier1,2* and Ted Abel3* Abstract Background: CREB-dependent transcription necessary for long-term memory is driven by interactions with CREB- binding protein (CBP), a multi-domain protein that binds numerous transcription factors potentially affecting expression of thousands of genes. Identifying specific domain functions for multi-domain proteins is essential to understand processes such as cognitive function and circadian clocks. We investigated the function of the CBP KIX domain in hippocampal memory and gene expression using CBPKIX/KIX mice with mutations that prevent phospho- CREB (Ser133) binding. Results: We found that CBPKIX/KIX mice were impaired in long-term memory, but not learning acquisition or short- term memory for the Morris water maze. Using an unbiased analysis of gene expression in the dorsal hippocampus after training in the Morris water maze or contextual fear conditioning, we discovered dysregulation of CREB, CLOCK, and BMAL1 target genes and downregulation of circadian genes in CBPKIX/KIX mice. Given our finding that the CBP KIX domain was important for transcription of circadian genes, we profiled circadian activity and phase resetting in CBPKIX/KIX mice.
    [Show full text]
  • Milk's Role As an Epigenetic Regulator in Health and Disease
    Review Milk’s Role as an Epigenetic Regulator in Health and Disease Bodo C. Melnik 1,* and Gerd Schmitz 2 1 Department of Dermatology, Environmental Medicine and Health Theory, Faculty of Human Sciences, University of Osnabrück, Am Finkenhügel 7a, D-49076 Osnabrück, Germany 2 Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, University of Regensburg, Franz-Josef-Strauß-Allee 11, D-93053 Regensburg, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-5241-988-060; Fax: +49-5241-25801 Academic Editor: Takeo Kubota Received: 7 January 2017; Accepted: 7 March 2017; Published: 15 March 2017 Abstract: It is the intention of this review to characterize milk’s role as an epigenetic regulator in health and disease. Based on translational research, we identify milk as a major epigenetic modulator of gene expression of the milk recipient. Milk is presented as an epigenetic “doping system” of mammalian development. Milk exosome-derived micro-ribonucleic acids (miRNAs) that target DNA methyltransferases are implicated to play the key role in the upregulation of developmental genes such as FTO, INS, and IGF1. In contrast to miRNA-deficient infant formula, breastfeeding via physiological miRNA transfer provides the appropriate signals for adequate epigenetic programming of the newborn infant. Whereas breastfeeding is restricted to the lactation period, continued consumption of cow’s milk results in persistent epigenetic upregulation of genes critically involved in the development of diseases of civilization such as diabesity, neurodegeneration, and cancer. We hypothesize that the same miRNAs that epigenetically increase lactation, upregulate gene expression of the milk recipient via milk-derived miRNAs.
    [Show full text]
  • Internet-Oheis Aineiston Taulukko. Valon Indusoimien Ja
    INTERNET-OHEIS AINEISTON TAULUKKO. Valon indusoimien ja kellokoneiston avainmolekyylien yhteydet sairauksiin. Geeni Eläinmallin ilmiasu Ihmisen sairaus Homer1 Masennus [1] ? Psykoosi [2] Oppimishäiriöt [3] Dementia [4] Nr4a1 Apoptoosin häiriöt [5] Masennus [26] Ylivilkkaus [6] Kaksisuuntainen mielialahäiriö [27] Sokeriaineenvaihdunnan häiriöt [7] Psykoosi [27] Ateroskleroosi [8] Akuutti myelooinen leukemia [28] Dementia [4] Rintasyöpä [29] Eturauhassyöpä [30] Melanooma [31] Alzheimerin tauti [32] Ateroskleroosi [33] Arntl1 Hedelmättömyys [9] Kaamosmasennus [34] Sokeriaineenvaihdunnan häiriöt [10] Kaksisuuntainen mielialahäiriö [35] Rasva-aineenvaihdunnan häiriöt [11] Verenpainetauti [36] Unihäiriöt [12] Tyypin 2 diabetes [36] Artropatia [13] Krooninen myelooinen leukemia [37] Sisäisen kellon arytmia [14] Clock Mania [15] Unihäiriöt [38] Metabolinen oireyhtymä [16] Metabolinen oireyhtymä [39] Kokaiiniriippuvuus [17] Lihavuus [39, 40] Rasvamaksa [41] Psykoosi [42] Npas2 Sisäisen kellon joustamattomuus [18] Kaamosmasennus [34] Muistihäiriöt [19] Non-Hodgkin-lymfooma [43] Rintasyöpä [44] Eturauhassyöpä [45] Autismi [46] Per1 Glukokortikoidituotannon häiriöt [20] Rintasyöpä [47,48] Ei-pienisoluinen keuhkosyöpä [49] Kohtusyöpä [50] Haimasyöpä [51] Krooninen myelooinen leukemia [37] Autismi [46] Per2 Alkoholin suurkulutus [21] Kaamosmasennus [34] Pahanlaatuinen lymfooma [22] Aikaistuneen univaiheen oireyhtymä [52] Endoteelin toimintahäiriöt [23] Akuutti myelooinen leukemia [53] Krooninen myelooinen leukemia [37] Rintasyöpä [47] Cry1, Cry2 Unihäiriöt [24] Krooninen myelooinen leukemia [37] Sokeriaineenvaihdunnan häiriöt [25] Eturauhassyöpä [45] 42 INTERNET-OHEISAINEISTON LÄHTEET 14) Bunger M, Wilsbacher L,Moran S, ym. receptors Nr4a3 and Nr4a1 leads to de- 1) Orsetti M, Di Brisco F, Canonico PL, Mop3 is an essential component of the velopment of acute myeloid leukemia. Genazzani AA, Ghi P. Gene regulation master circadian pacemaker in mam- Nat Med 2007;13:730–5. in the frontal cortex of rats exposed to mals. Cell 200;103:1009–17.
    [Show full text]
  • Counteracting CAR T Cell Dysfunction
    Oncogene (2021) 40:421–435 https://doi.org/10.1038/s41388-020-01501-x REVIEW ARTICLE Counteracting CAR T cell dysfunction 1,2 1 1 1 2 Mansour Poorebrahim ● Jeroen Melief ● Yago Pico de Coaña ● Stina L. Wickström ● Angel Cid-Arregui ● Rolf Kiessling 1 Received: 6 May 2020 / Revised: 22 September 2020 / Accepted: 30 September 2020 © The Author(s) 2020. This article is published with open access Abstract In spite of high rates of complete remission following chimeric antigen receptor (CAR) T cell therapy, the efficacy of this approach is limited by generation of dysfunctional CAR T cells in vivo, conceivably induced by immunosuppressive tumor microenvironment (TME) and excessive antigen exposure. Exhaustion and senescence are two critical dysfunctional states that impose a pivotal hurdle for successful CAR T cell therapies. Recently, modified CAR T cells with an “exhaustion- resistant” phenotype have shown superior antitumor functions and prolonged lifespan. In addition, several studies have indicated the feasibility of senescence delay in CAR T cells. Here, we review the latest reports regarding blockade of CAR T cell exhaustion and senescence with a particular focus on the exhaustion-inducing pathways. Subsequently, we describe what potential these latest insights offer for boosting the potency of adoptive cell transfer (ACT) therapies involving CAR T cells. 1234567890();,: 1234567890();,: Furthermore, we discuss how induction of costimulation, cytokine exposure, and TME modulation can impact on CAR T cell efficacy and persistence, while potential safety issues associated with reinvigorated CAR T cells will also be addressed. Introduction persistence in the hostile tumor microenvironment (TME) represent additional key impediments to efficacious CAR T In a recent decade, genetically modified immune cells, parti- cell responses and durable clinical remission following CAR T cularly chimeric antigen receptor (CAR) T cells, have raised cell therapy [4].
    [Show full text]
  • Dibutyl Phthalate Disrupts Conserved Circadian Rhythm in Drosophila and Human Cells
    Science of the Total Environment 783 (2021) 147038 Contents lists available at ScienceDirect Science of the Total Environment journal homepage: www.elsevier.com/locate/scitotenv Dibutyl phthalate disrupts conserved circadian rhythm in Drosophila and human cells Wen Liu a,⁎,1, Hao Cao a,1, Sifang Liao a,Błażej Kudłak b, Michael J. Williams a, Helgi B. Schiöth a,c a Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden b Department of Analytical Chemistry, Faculty of Chemistry, Gdańsk University of Technology, Gdańsk, Poland c Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia HIGHLIGHTS GRAPHICAL ABSTRACT • DBP disrupts circadian regulation genes at transcriptional level. • DBP affects circadian pattern, but does not affect eye morphology. • It is of great significance to extend envi- ronmental pollutants exposure studies with circadian rhythm research. article info abstract Article history: People are constantly exposed to phthalates, due to their common use in the production of plastics, pharmaceu- Received 18 February 2021 ticals, cosmetics and skin care products. The ability of phthalates to disrupt endocrine signaling, leading to devel- Received in revised form 18 March 2021 opmental, reproductive and metabolic defects, has been studied, yet how phthalates interfere with these Accepted 5 April 2021 biological functions is still unclear. To uncover DBP interacting molecular pathways, we raised Drosophila Available online 15 April 2021 melanogaster on food containing dibutyl phthalate (DBP) at various concentrations. Whole transcriptome analy- Editor: Damia Barcelo sis of adult Drosophila reveals that DBP exposure throughout development disrupts the expression of genes cen- tral to circadian rhythm regulation, including increased expression of vrille (vri, human NFIL3), timeless (tim, human TIMELESS)andperiod (per, human PER3), with decreased expression of Pigment-dispersing factor (Pdf).
    [Show full text]
  • The Stress-Induced Transcription Factor NR4A1 Adjusts Mitochondrial Function and Synapse Number in Prefrontal Cortex
    This Accepted Manuscript has not been copyedited and formatted. The final version may differ from this version. A link to any extended data will be provided when the final version is posted online. Research Articles: Cellular/Molecular The stress-induced transcription factor NR4A1 adjusts mitochondrial function and synapse number in prefrontal cortex Freddy Jeanneteau1, Christian Barrère1, Mariska Vos2, Carlie JM. De Vries2, Claude Rouillard3, Daniel Levesque4, Yann Dromard1, Marie-Pierre Moisan5, Vanja Duric6, Tina C. Franklin7, Ronald S. Duman7, David A. Lewis8, Stephen D. Ginsberg9 and Margarita Arango-Lievano1 1Dép. de Neuroscience et Physiologie, Institut de génomique fonctionnelle, INSERM, CNRS, Université de Montpellier, France. 2Dep. of Medical Biochemistry, Academic Medical Center, University of Amsterdam, The Netherlands. 3Dép. de Psychiatrie et Neuroscience, Université Laval, Québec, Canada. 4Faculté de Pharmacie, Université de Montréal, Canada. 5Nutrition and Integrative Neurobiology, INRA, Université de Bordeaux, France. 6Dep. of Physiology & Pharmacology, Des Moines University, IA, USA. 7Dep. of Psychiatry and Neurobiology, Yale University, New Haven, CT, USA. 8Dep. of Psychiatry, University of Pittsburgh, PA, USA. 9Nathan Kline Institute, Orangeburg, USA and Dep. of Psychiatry, Neuroscience & Physiology, NYU Langone Medical Center, New York, NY, USA. DOI: 10.1523/JNEUROSCI.2793-17.2017 Received: 25 September 2017 Revised: 10 November 2017 Accepted: 8 December 2017 Published: 2 January 2018 Author contributions: F.J., S.D.G., and M.A.-L. designed research; F.J., C.B., M.V., C.J.D.V., C.R., D.L., Y.D., V.D., T.F., R.S.D., D.A.L., and M.A.-L. performed research; F.J., C.J.D.V., C.R., D.L., V.D., R.S.D., D.A.L., S.D.G., and M.A.-L.
    [Show full text]